Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Dovitinib in Solid Tumors
NCT02116803Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of dovitinib in solid tumor, sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
dovitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02116803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116803.